Alternative human drug anti-Kir channel intensive searches are on going worldwide focused on particular channelopathies. Some of these examples are trying to identify highly specific and more potent drug-like compounds to target defined human Kir channels, including repurposing of approved drugs. Public examples of approved drugs presently being tested to control human channelopathies are for instance, Retigabine (tested as antiepileptic drug ), Dofetilide (tested as antiarrhythmic for atrial fibrillation , and Senicapoc (tested against ischemic stroke despite showing off-target effects ). Future research may lead to new discoverings in the anti-channelopathies research field, but progress is slow mostly due to the small amount of drug-like compound alternatives and to the extensive clinical tests required for each possibility.